Physician profile
Sanjay Agarwal
NPI 1114548864
$7,367.09
in general payments reported to CMS, 2019-2025
26 companies · $641 in 2025
The $641 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $1,740 · 2023: $2,592 · 2024: $1,936 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,971 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,970.88 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $915.52 | 2022-2025 | Rinvoq |
| Genzyme Corporation | $780.71 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $767.74 | 2021-2024 | Dupixent, Libtayo |
| Lilly USA, LLC | $673.73 | 2021-2024 | Olumiant, Taltz |
| Dermavant Sciences, INC. | $663.08 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $416.12 | 2021-2025 | |
| Ucb, INC. | $387.40 | 2022-2024 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $369.06 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $347.58 | 2022-2024 | Sotyktu |
| Incyte Corporation | $339.97 | 2022-2024 | Opzelura |
| Janssen Biotech, INC. | $333.29 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $238.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.32 | 2023-2024 | Spevigo |
| Pfizer INC. | $211.76 | 2021-2023 | |
| Amgen INC. | $167.11 | 2021-2024 | Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $154.42 | 2022-2023 | Tremfya |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Kyowa Kirin, INC. | $71.22 | 2022-2024 | Poteligeo |
| Leo Pharma INC. | $40.01 | 2022 | |
| Lnhc, INC | $39.30 | 2025 | Zelsuvmi |
| Galderma Laboratories, L.P. | $33.14 | 2025 | Nemluvio |
| Astrazeneca Pharmaceuticals LP | $25.27 | 2023 | |
| Biofrontera INC. | $22.44 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.50 | 2025 | Siliq |
| Botanix Sb INC | $18.36 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $15.53 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Agarwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.